Today: 20 May 2026
Woodside Energy stock (ASX:WDS) closes higher as oil steadies; Jan 28 update is next test

Woodside Energy stock (ASX:WDS) closes higher as oil steadies; Jan 28 update is next test

Sydney, Jan 8, 2026, 17:59 AEDT — After-hours

  • Woodside shares closed up 0.4% at A$22.95
  • Crude rebounded on a U.S. inventory draw, with Venezuela headlines still driving swings
  • Next catalyst is Woodside’s fourth-quarter report on Jan. 28

Woodside Energy Group Ltd (WDS.AX) shares ended Thursday up 0.4% at A$22.95, as investors took another cue from oil after a choppy start to the year.

The small move matters because traders have been pricing Woodside like a macro lever: oil up, Woodside steadies; oil down, Woodside slips. The next company update lands in a market that is trying to decide whether 2026 starts with too much supply.

Woodside’s calendar shows a fourth-quarter 2025 report due on Jan. 28, followed by its 2025 annual report on Feb. 24. That quarterly update is the next close look at production, sales and realised prices, plus any commentary on spending for liquefied natural gas (LNG) projects.

Oil edged higher earlier on Thursday after two days of declines, helped by a larger-than-expected fall in U.S. crude stocks, Reuters reported. “Pullback buying has nudged prices slightly higher, but persistent oversupply concerns are capping upside momentum,” said Mitsuru Muraishi, an analyst at Fujitomi Securities. Reuters

The sector is also moving into earnings season with a cautious tone. Exxon Mobil said lower crude prices could cut fourth-quarter upstream earnings — its oil and gas production business — by about $800 million to $1.2 billion, a filing showed.

On the chart, MarketScreener data put near-term support around A$22.80 — a level traders see as a possible floor if buyers return — with resistance near A$24.16, where selling has tended to appear. Woodside is down 3.0% over five days and 2.7% since Jan. 1.

But the tape can turn fast. U.S. moves to redirect Venezuelan barrels and seize tankers have already pushed prices around on shifting supply expectations, and that kind of volatility can spill into energy shares.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI
Previous Story

Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet
Next Story

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet

Go toTop